Jazeta

Sitagliptin Hydrochloride, the active ingredient in Jazeta, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults when used with diet and exercise.

GNH USA supplies Jazeta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Jazeta is a DPP‑4 inhibitor used to improve glycaemic control in patients with type 2 diabetes. - Type 2 diabetes mellitus: lowers blood glucose levels when combined with diet and exercise. - Combination therapy: enhances glycaemic control when added to metformin or other antidiabetic agents. - Adjunct to lifestyle modification: supports patients who need additional pharmacologic support to achieve target HbA1c.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Headache: transient cranial discomfort. - Nasopharyngitis: upper respiratory tract infection symptoms. - Upper respiratory infection: cough, sore throat. - Dizziness: occasional light‑headedness. - Hypoglycaemia (when combined with insulin or sulfonylureas): low blood sugar episodes.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Joint pain: unexplained arthralgia. - Hepatic injury: elevated liver enzymes. - Bullous pemphigoid: blistering skin disorder. - Severe hypoglycaemia: especially in patients on insulin or sulfonylureas.

Before initiating Jazeta, consider the following precautions: - Renal function: adjust dose in patients with moderate to severe renal impairment. - Hepatic function: use with caution in patients with liver disease. - Hypoglycaemia risk: monitor blood glucose closely when combined with insulin or sulfonylureas. - Pancreatitis: discontinue if signs of pancreatic inflammation appear. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. - Store at room temperature: keep in the original container, protect from moisture and heat.

Jazeta may interact with several medicines; review patient medication profiles carefully. Major Interactions (Avoid): - Insulin or sulfonylureas: increased risk of hypoglycaemia. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise sitagliptin plasma levels. - Rifampin: may reduce sitagliptin exposure, decreasing efficacy. Moderate Interactions (Monitor Closely): - Diuretics: potential impact on glucose control. - ACE inhibitors: monitor renal function and electrolytes. - Warfarin: observe INR values for possible alterations.